Trial
NCT01062230
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Arkansas
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Multiple Myeloma
Intervention
Bortezomib (Velcade)
Why stopped
Slow accrual; PI left primary institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-06